140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients

Introduction: Current available data is unclear regarding the effects of concomitant amiodarone on apixaban pharmacokinetics (PK) despite their use in nonvalvular atrial fibrillation (NVAF). Amiodarone's long and variable half-life makes a traditional crossover drug study challenging. This ongoing retrospective study will define the mechanism of this potential drug interaction. The primary objective is to describe the impact of amidarone on pharmacokinetic exposure of apixaban in hospitalized patients with a history of NVAF who are on a stable dose of amiodarone 200 mg/day.